Novo Nordisk CEO Mike Doustdar told CNBC ↗ on May 6 that the Wegovy ↗ brand now holds 65% of all new US GLP-1 prescriptions, characterizing the moment as a "turnaround situation" for the franchise. The Q1 disclosure also confirmed that Novo terminated the single-chamber CagriSema co-formulation project, citing portfolio considerations. The dual-chamber CagriSema injectable system continues, with the original FDA filing already submitted and a regulatory decision expected late 2026.
The market share read. 65% of new US GLP-1 prescriptions is the metric that matters most for new-patient acquisition. Novo's franchise (Wegovy injectable, Wegovy pill, Ozempic ↗, Rybelsus ↗) collectively writes 65% of every fresh prescription started; Lilly's franchise (Mounjaro ↗, Zepbound ↗, Foundayo) writes 35%. The number is consistent with the 20:1 oral GLP-1 ratio ↗ the section flagged on May 4 between Wegovy pill and Foundayo, and with the Q1 print's volume strength on both injectable and oral semaglutide ↗ products. The "turnaround" framing reflects Novo's market position before the Wegovy pill launch, when commercial sentiment was running heavily against the franchise on price-erosion and pipeline-second-place concerns.
The CagriSema device decision. CagriSema is the GLP-1 plus amylin combination Novo has been advancing through Phase 3 since the disappointing February 2025 readout that failed to match Zepbound on weight loss. The original development plan included two delivery devices: a dual-chamber injectable (separate compartments for semaglutide and cagrilintide ↗, mixed at injection) and a single-chamber co-formulation (premixed solution). The dual-chamber device is what Novo filed with FDA and what supports the pending regulatory decision. The single-chamber co-formulation has now been discontinued. Novo's framing is "portfolio considerations," which most likely reflects either chemistry-CMC challenges in producing a stable single-chamber product or commercial-strategy decisions to focus on the dual-chamber path.
The CEO's commentary. Doustdar's "turnaround situation" framing, paired with the 65% market-share statement, is meant to reset investor expectations after eighteen months of Novo underperforming Lilly on share price and analyst sentiment. The timing matters: Doustdar took the CEO role earlier this year, and the May 6 CNBC interview is one of the first major media appearances laying out his strategic narrative. The volume data on Wegovy pill (1.3 million Q1 prescriptions, 2 million-plus cumulative since the January launch) and the guidance tightening (-5/-13% to -4/-12%) are the operational underpinnings of the narrative.
The competitive pushback. Jefferies analysts pushed back the same day, arguing that the guidance change was unlikely to lift consensus forecasts and could even contract them: "we suspect the fact that the company has not lifted the lower end of the guidance range more will be seen as a negative." The framing matters because NVO US-listed shares had already risen ~6% on the print, and the price-war pressure on the GLP-1 class (with Wegovy pill running at $149/month for the 1.5 mg starter dose against intensifying Foundayo competition) leaves the lower-end risk path open through year-end. The bull and bear cases both exist; the difference is whether the volume momentum is sustainable or whether price pressure compresses further in H2.
Why CagriSema device cut matters. The single-chamber co-formulation was the product packaging that consumer-facing marketing typically prefers (one injection, one cartridge, simpler patient experience). Discontinuing it adds a small operational friction to CagriSema's commercial launch. The dual-chamber device is functionally equivalent but requires the patient to mix two compartments at injection. This is not a clinical setback (both devices deliver the same active ingredients) but it is a marketing setback compared with what Novo originally planned. CagriSema is the company's hedge against retatrutide ↗ and the next wave of triple- and quadruple-agonist obesity drugs; the device decision reflects Novo prioritizing the path most likely to reach approval on time over the path that would have given marketing a slightly cleaner story.
The platform read. The GLP-1R ↗ and CALCR/RAMP ↗ target pages on peptidemodel anchor the Novo franchise's mechanistic profile: GLP-1 receptor for semaglutide, calcitonin-amylin receptor complex for cagrilintide. The combination of GLP-1(7-36) amide ↗ and Pramlintide on the platform is the closest peptide-card analogue to what CagriSema delivers as a finished drug product. The ECO 2026 meeting in Istanbul (May 12-15) is the next venue where CagriSema body composition and efficacy data are expected to land.
What 2026 still has to reveal. Whether Novo holds 65% market share through the end of the year as Foundayo's launch matures and Lilly's sales force pushes back. Whether CagriSema's late-2026 regulatory decision converts to a 2027 launch, and whether the dual-chamber device actually reaches patients without further design iterations. And whether the H2 price-war pressure that Jefferies flagged materializes or the volume momentum that Doustdar described carries through. Each is testable within the year.